Non-small-cell lung cancer with HER2 exon 20 mutation: Regression with dual HER2 inhibition and anti-vegf combination treatment

Journal of Thoracic Oncology

Volumn 8, Issue 2, 2013, Pages

  Falchook, Gerald S ^a   Janku, Filip ^a   Tsao, Anne S ^a   Bastida, Christel C ^a   Stewart, David J ^b   Kurzrock, Razelle ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PEMETREXED; TRASTUZUMAB;

ADULT; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYBERKNIFE; EXON; FEMALE; GENE MUTATION; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873830350     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827ce38e     Document Type: Article

References (5)

1. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-526.
2. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38.
3. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;354:2619-2621.
4. Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol 2012;30:1505-1512.
5. Weihua Z, Tsan R, Huang WC, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-393.